Apogee Buy Delivers Eczema Trial Win for AbbVie
AbbVie said the mid-dose regimen cut skin lesions and itch versus placebo in 346 patients, supporting a Phase 3 study of the investigational antibody.
4 Articles
4 Articles
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater...
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
Plus news about Sarepta, Rafael Holdings, Sagimet, Pyxis Oncology, Connect Biopharma, Asahi Kasei, Astrocyte Pharmaceuticals, GSK, Wave and Kailera. AbbVie unveils Phase 2 data for Apogee drug: Zumilokibart, an anti-IL-13 antibody, produced statistically significant benefits ...
AbbVie Inc. (ABBV) Stock: Rebounds as Zumilokibart Shows Strong Skin and Itch Improvement Results
TLDR AbbVie stock recovered after positive Phase 2 zumilokibart study results. Zumilokibart improved skin clearance and itch reduction in atopic dermatitis. APEX Part B study evaluated multiple doses across 346 adult patients. AbbVie plans Phase 3 development with the mid-dose treatment approach. The results strengthen AbbVie’s expanding immunology research pipeline. AbbVie Inc. (ABBV) stock recovered [...]
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
